Myogen completes enrollment in heart failure Phase IIIs

MYOG completed enrollment of a total of 1,800 advanced chronic heart failure patients in two Phase III trials of its enoximone capsules. The identical double-blind, placebo-controlled trials are being run in North and South America (ESSENTIAL I) and in Europe (ESSENTIAL II). The three primary endpoints are time from randomization to cardiovascular hospitalization or all-cause mortality, six-minute walk distance and patient global assessment. ...